FDA Softens 'Dear Doctor' Letter Guidance For Drugmakers

Law360, New York (July 9, 2013, 8:04 PM EDT) -- The U.S. Food and Drug Administration backed down Tuesday from its recommendation that drugmakers evaluate the impact of their letters alerting physicians to new safety information about a drug, after manufacturers complained the request was too burdensome.

The FDA released draft guidance in November 2010 that advised drugmakers when and how to send so-called dear doctor letters, which are used to alert health care professionals to previously unknown adverse reactions linked to a drug, changes in dosage that could improve a drug's effectiveness and other important...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.